tldrdailynews.com logo
Tag

Diagnostics

All articles tagged with #diagnostics

Handheld cancer detector nears home-based early-detection breakthrough
science19 hours ago

Handheld cancer detector nears home-based early-detection breakthrough

Researchers at Westlake University in China have unveiled a handheld cancer-screening device that can detect early-stage cancer biomarkers from a single blood drop. Using a compact 3D metamaterial Bound States-in-the-Continuum sensing chip, the device replaces bulky laboratory equipment with a portable chip, LED, and photodetector, enabling at-home or remote testing. In trials with 171 patient serum samples, it achieved 94.9% accuracy for early cancer detection and 92.1% for post-surgery monitoring—far outperforming the standard ELISA method (74.7%). The team also claims mass production of thousands of identical chips per wafer at about $5 per chip. Findings were published in Nature Photonics and demonstrated 10,000x greater sensitivity than ELISA in spotting lung-cancer biomarkers.

via Interesting Engineering|
#biomarkers#cancer#diagnostics
Cruise-ship hantavirus outbreak exposes gaps in early diagnosis and prevention
opinions13 days ago

Cruise-ship hantavirus outbreak exposes gaps in early diagnosis and prevention

In a Washington Post opinion, Abraar Karan argues that the Hondius hantavirus outbreak—and a prior Argentina incident—expose how slow recognition and limited on-site testing hinder outbreak control. Hantavirus can spread between people and cause severe heart-lung illness, with symptoms that are often non-specific and appear weeks after exposure, making early diagnosis challenging. The piece advocates more proactive travel-health screening, broader and faster diagnostics (like metagenomic sequencing and PCR panels), and greater investment in point-of-care tests to curb shipboard and cross-border transmission, while noting cost and biosafety barriers remain substantial.

via The Washington Post|
#diagnostics#hantavirus#opinions
WHO backs near-point-of-care TB tests and tongue swabs to speed diagnosis
health2 months ago

WHO backs near-point-of-care TB tests and tongue swabs to speed diagnosis

WHO endorses portable, near-point-of-care TB tests that are battery-powered and deliver results in under an hour, plus tongue-swab sampling and sputum pooling to expand testing, cut costs, and start treatment sooner; the guidance, released for World TB Day 2026, calls for urgent scale-up and sustained investment as funding gaps threaten progress, with potential benefits for testing other diseases as well.

via World Health Organization (WHO)|
#diagnostics#health#point-of-care
Abbott to close Exact Sciences acquisition, expanding cancer diagnostics leadership
business2 months ago

Abbott to close Exact Sciences acquisition, expanding cancer diagnostics leadership

Abbott expects to close its acquisition of Exact Sciences on March 23, 2026 after regulatory clearances, adding Exact’s cancer-screening and precision-oncology portfolio (Cologuard, Oncotype DX, Oncodetect, Cancerguard) to expand Abbott’s diagnostics leadership. The deal is projected to bring about $3 billion of incremental sales in 2026, accelerate Abbott’s growth in diagnostics, and dilute 2026 adjusted EPS by about $0.20, as the company aims to make cancer detection and management more accessible.

via Abbott MediaRoom|
#abbott#business#cancer-screening
Grail's Galleri multi-cancer test misses primary endpoint in NHS study, fueling skepticism
biotech3 months ago

Grail's Galleri multi-cancer test misses primary endpoint in NHS study, fueling skepticism

Grail's Galleri blood test for early cancer detection failed to meet its primary endpoint in a large NHS-backed study, renewing questions about its clinical utility despite some detected benefits. Grail reported selling 185,000 tests in 2025 for $136.8 million, and its stock fell about 47% after hours following the setback.

via statnews.com|
#biotech#cancer-detection#diagnostics
business3 months ago

Danaher to Acquire Masimo in a $9.9 Billion Diagnostics Play

Danaher announced a definitive agreement to acquire Masimo for $180 per share in cash, valuing Masimo at about $9.9 billion including debt and net cash. The deal, which translates to roughly 18x 2027 EBITDA (or 15x with expected synergies), would make Masimo a standalone operating company within Danaher’s Diagnostics segment. Masimo is expected to be accretive to adjusted diluted EPS by $0.15–$0.20 in the first full year and about $0.70 in year five, with long-term high-single-digit core revenue growth and over $530 million in EBITDA in 2027. Danaher also expects more than $125 million of annual cost synergies and over $50 million of annual revenue synergies by the fifth full year post-close. The transaction is targeted to close in the second half of 2026, subject to regulatory approvals, Masimo shareholder approval, and other customary conditions; financing will come from cash on hand and debt. Advisors named include Citi and Goldman Sachs for Danaher, with Kirkland & Ellis as legal counsel.

via Danaher Corporation Investors|
#acquisition#business#danaher
Four advances aim to outpace antibiotic resistance and reboot modern medicine
science-tech4 months ago

Four advances aim to outpace antibiotic resistance and reboot modern medicine

Antibiotic resistance threatens a century of medical progress, but four broad advances are reshaping the landscape: faster, on-site diagnostics; expansion beyond traditional antibiotics through nontraditional therapies (including bacteriophages and microbiome-based approaches and CRISPR antimicrobials); recognizing resistance spreads across ecosystems with One Health approaches; and policy reforms to incentivize antibiotic development, aiming to diagnose earlier, widen treatment options, and safeguard medicines for the future.

via The Conversation|
#antibiotic-resistance#bacteriophage-therapy#diagnostics
Abbott posts strong 2025 earnings, outlines 2026 growth plan and strategic moves
business4 months ago

Abbott posts strong 2025 earnings, outlines 2026 growth plan and strategic moves

Abbott reported Q4 2025 GAAP EPS of $1.01 and adjusted EPS of $1.50 (up 12%), and full-year 2025 sales of $44.3B with adjusted EPS of $5.15 (up 10%). For 2026, it guides organic sales growth of 6.5%–7.5% and adjusted EPS of $5.55–$5.80 (about 10% at the midpoint). The company also plans to close its Exact Sciences acquisition in Q2 2026 to expand cancer diagnostics, announced regulatory advances in electrophysiology and ablation, and declared a quarterly dividend of $0.63.

via Abbott MediaRoom|
#2025-results#2026-outlook#abbott
SPARDA: Kamikaze bacterial defense could spark new biotech tools
science4 months ago

SPARDA: Kamikaze bacterial defense could spark new biotech tools

Live Science reports on SPARDA, a kamikaze-like bacterial defense system that sacrifices infected cells to prevent the spread of invaders. Scientists mapped SPARDA’s beta-relay switches in argonaute proteins with AlphaFold, revealing a self-destruct mechanism that activates in response to threats and can form DNA‑degrading chains. While SPARDA naturally guards bacteria, researchers see potential to repurpose it for diagnostics and other biotech tools, offering a CRISPR‑alternative route that could broaden target flexibility in detecting pathogens.

via Live Science|
#argonaute#bacteria#biotechnology